Skip to main content

David Charles Montefiori, PhD

Professor of Surgery
Office: Surgical Oncology Res Fac, Durham, NC 27710
Campus Mail: DUMC Box 2926 Med Ctr, Durham, NC 27710

Dr. Montefiori is Professor and Director of the Laboratory for AIDS Vaccine Research and Development in the Department of Surgery, Division of Surgical Sciences, Duke University Medical Center. His major research interests are viral immunology and AIDS vaccine development, with a special emphasis on neutralizing antibodies. One of his highest priorities is to identify immunogens that generate broadly cross-reactive neutralizing antibodies for inclusion in HIV vaccines.  Many aspects of the neutralizing antibody response are studied in his laboratory, including mechanisms of neutralization and escape, epitope diversity among genetic subtypes and geographic origins, ontogeny of broadly neutralizing antibody responses and computationally-assisted vaccine design. Over the years he has explored multiple types of assays for neutralizing antibodies and other potential antiviral antibodies, focusing on assay optimization, standardization, validation and high throughput. The scope of research covers HIV-infected individuals and nonhuman primate models of simian immunodeficiency virus (SIV) and simian-human immunodeficiency virus (SHIV) infection.  Dr. Montefiori also directs a large AIDS vaccine immune monitoring program, which operates in compliance with Good Clinical Laboratory Practice and has served as a national and international resource for standardized assessments of neutralizing antibody responses in preclinical and clinical trials of candidate AIDS vaccines since 1988. In 2002 he chaired the Antibody Laboratory Standardization Working Group that assisted in the design of the Global HIV Vaccine Enterprise Strategic Plan for HIV vaccines. He currently directs the Core Neutralizing Antibody Laboratories for the HIV Vaccine Clinical Trials Network (HVTN), the NIH Preclinical HIV-1 Vaccine Program and the Center for HIV/AIDS Vaccine Immunology- Immunogen Design (CHAVI-ID). He also directs a large Comprehensive Antibody Vaccine Immune Monitoring Consortium (CAVIMC) as part of the Bill and Melinda Gates Foundation's Collaboration for AIDS Vaccine Discovery (CAVD). He has published over 500 original research papers that have helped shape the scientific rationale for antibody-based HIV-1 vaccines.

Education and Training

  • Ph.D., Clemson University, 1982

Publications

Jones, Andrew T., Xiaoying Shen, Korey L. Walter, Celia C. LaBranche, Linda S. Wyatt, Georgia D. Tomaras, David C. Montefiori, et al. “HIV-1 vaccination by needle-free oral injection induces strong mucosal immunity and protects against SHIV challenge.” Nat Commun 10, no. 1 (February 18, 2019): 798. https://doi.org/10.1038/s41467-019-08739-4.

Full Text

Ringe, Rajesh P., Pavel Pugach, Christopher A. Cottrell, Celia C. LaBranche, Gemma E. Seabright, Thomas J. Ketas, Gabriel Ozorowski, et al. “Closing and Opening Holes in the Glycan Shield of HIV-1 Envelope Glycoprotein SOSIP Trimers Can Redirect the Neutralizing Antibody Response to the Newly Unmasked Epitopes.” J Virol 93, no. 4 (February 15, 2019). https://doi.org/10.1128/JVI.01656-18.

Full Text

Bresk, C Anika, Tamara Hofer, Sarah Wilmschen, Marina Krismer, Anja Beierfuß, Grégory Effantin, Winfried Weissenhorn, et al. “Induction of Tier 1 HIV Neutralizing Antibodies by Envelope Trimers Incorporated into a Replication Competent Vesicular Stomatitis Virus Vector.” Viruses 11, no. 2 (February 15, 2019). https://doi.org/10.3390/v11020159.

Full Text

Asbach, Benedikt, Karen V. Kibler, Josef Köstler, Beatriz Perdiguero, Nicole L. Yates, Sherry Stanfield-Oakley, Georgia D. Tomaras, et al. “Priming with a Potent HIV-1 DNA Vaccine Frames the Quality of Immune Responses prior to a Poxvirus and Protein Boost.” In J Virol, Vol. 93, 2019. https://doi.org/10.1128/JVI.01529-18.

Full Text

Kibler, Karen V., Benedikt Asbach, Beatriz Perdiguero, Juan García-Arriaza, Nicole L. Yates, Robert Parks, Sherry Stanfield-Oakley, et al. “Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVAC.” J Virol 93, no. 3 (February 1, 2019). https://doi.org/10.1128/JVI.01513-18.

Full Text

Pantaleo, Giuseppe, Holly Janes, Shelly Karuna, Shannon Grant, Laissa Ouedraogo, Mary Allen, Georgia D. Tomaras, et al. “Co-Administration of HIV Env Protein with DNA and/or NYVAC Vaccines in Humans Results in Earlier and Potent Generation of Anti-Env Antibody Responses.” The Lancet Hiv, Volume 6, no. 11 (January 25, 2019).

Scholars@Duke

Bricault, Christine A., Karina Yusim, Michael S. Seaman, Hyejin Yoon, James Theiler, Elena E. Giorgi, Kshitij Wagh, et al. “HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design.” Cell Host Microbe 25, no. 1 (January 9, 2019): 59-72.e8. https://doi.org/10.1016/j.chom.2018.12.001.

Full Text

Mielke, Dieter, Gama Bandawe, Justin Pollara, Melissa-Rose Abrahams, Tinashe Nyanhete, Penny L. Moore, Ruwayhida Thebus, et al. “Antibody-Dependent Cellular Cytotoxicity (ADCC)-Mediating Antibodies Constrain Neutralizing Antibody Escape Pathway.” Front Immunol 10 (2019): 2875. https://doi.org/10.3389/fimmu.2019.02875.

Full Text

Rosenberg, Yvonne J., George K. Lewis, David C. Montefiori, Celia C. LaBranche, Mark G. Lewis, Lori A. Urban, Jonathan P. Lees, Lingjun Mao, and Xiaoming Jiang. “Introduction of the YTE mutation into the non-immunogenic HIV bnAb PGT121 induces anti-drug antibodies in macaques.” Plos One 14, no. 2 (2019): e0212649. https://doi.org/10.1371/journal.pone.0212649.

Full Text

Bonsignori, Mattia, Eric Scott, Kevin Wiehe, David Easterhoff, S Munir Alam, Kwan-Ki Hwang, Melissa Cooper, et al. “Inference of the HIV-1 VRC01 Antibody Lineage Unmutated Common Ancestor Reveals Alternative Pathways to Overcome a Key Glycan Barrier.” Immunity 49, no. 6 (December 18, 2018): 1162-1174.e8. https://doi.org/10.1016/j.immuni.2018.10.015.

Full Text

Pages